ECS Botanics is set to launch AVANI AVA, a new medicinal cannabis range specifically designed for women’s health, aiming to capture a growing market segment with targeted formulations.
- Launch of AVANI AVA brand in January 2026
- Product range includes pessaries, capsules, topical cream, and flower
- Focus on addressing women’s health conditions under Australia’s SAS-B scheme
- Strengthens ECS’s B2C portfolio and expands pharmacy and export channels
- Leverages ECS’s vertically integrated operations and formulation expertise
ECS Botanics Targets Women’s Health with New Cannabis Range
Medicinal cannabis company ECS Botanics Holdings Ltd (ASX, ECS) has announced the upcoming launch of AVANI AVA, a new product line designed specifically to meet the health needs of women. Scheduled for release in January 2026, this range reflects a strategic move to address a notable trend in Australia’s medicinal cannabis market, where women now represent over 40% of approvals under the Special Access Scheme Category B (SAS-B).
Recognising the rising demand for gender-specific treatments, ECS has developed AVANI AVA to provide targeted relief for conditions commonly reported by female patients. The product suite includes pessaries, capsules, topical creams, and flower, each formulated with precise cannabinoid profiles and delivery methods tailored to women’s health requirements.
A Thoughtful Product Mix for Targeted Relief
The initial AVANI AVA range features a 5mg THC / 25mg CBD pessary designed for rapid, localized delivery, addressing unmet needs in women’s health. Complementing this are low-dose 5mg THC capsules for controlled oral dosing, a 200mg THC / 200mg CBD topical cream infused with terpene-inspired aromas for localized application, and a flower cultivar with 22% THC noted for its sweet, fruity aroma and balanced terpene profile preferred by female patients.
These formulations leverage ECS’s vertically integrated operations and expertise in medicinal cannabis production, ensuring quality and consistency. The company’s Managing Director, Nan-Maree Schoerie, emphasised the brand’s commitment to clinically relevant, trusted products that open new dialogues with prescribers and pharmacists specialising in women’s health.
Strategic Growth Across Channels
AVANI AVA is positioned to strengthen ECS’s differentiated business-to-consumer portfolio while supporting growth across pharmacy, prescriber, and export channels throughout 2026. By focusing on a demographic that is increasingly significant in medicinal cannabis approvals, ECS aims to deepen engagement with healthcare professionals and expand its market footprint both domestically and internationally.
This launch also aligns with ECS’s broader sustainability and quality commitments, as the company utilises regenerative horticultural practices and renewable energy in its cultivation processes. The introduction of AVANI AVA could mark a pivotal step in ECS’s evolution as a leader in specialised medicinal cannabis products.
Bottom Line?
AVANI AVA’s launch signals ECS Botanics’ strategic bet on women’s health, with potential to reshape its market presence in 2026.
Questions in the middle?
- How will prescribers and pharmacists respond to the gender-specific formulations of AVANI AVA?
- What are ECS’s sales targets and market share expectations for AVANI AVA in its first year?
- How might competitors react to ECS’s focused approach on women’s medicinal cannabis products?